·临床药学·

羟基喜树碱膀胱灌注联合热疗对浅表性膀胱癌术后复发的影响研究

任启明，李健，郭萍

(莱芜市食品药品检验检测中心，山东 莱芜 271100)

摘要：目的研究羟基喜树碱(HCPT)膀胱灌注联合热疗对浅表性膀胱癌术后复发的影响。方法选择114例浅表性膀胱癌行经尿道膀胱肿瘤电切术患者为研究对象，采用随机数字表法分为观察组和对照组各57例，对照组单纯采用羟基喜树碱膀胱内灌注化疗，观察组采用羟基喜树碱膀胱内灌注联合体外热疗。比较两组复发情况及远期生存率。结果观察组6个月、1年、1.5年、2年复发率均明显低于对照组(3.51% vs 19.30%,10.53% vs 24.56%,14.04% vs 29.82%,14.04% vs 35.09%)；2年生存率明显高于对照组(87.72% vs 73.68%)。结论羟基喜树碱膀胱灌注联合热疗能有效降低浅表性膀胱癌术后复发率，提高远期生存率。

关键词：浅表性膀胱癌；羟基喜树碱；热疗；复发

作者简介：任启明，男，主管药师，研究方向：药品监管抽样，E-mail:lwcfda@163.com

中图分类号：R969.4文献标识码：A

Effects research of HCPT bladder perfusion combined hyperthermia on preventing

recurrence postoperative of superficial bladder cancer

RENQi-ming,LIJian,GUOPing

(LaiwuCenterforFoodandDrugControl,Laiwu271100,China)

Abstract：ObjectiveTo study the effect of HCPT bladder perfusion combined hyperthermia on preventing recurrence postoperative of superficial bladder cancer.Methods114 cases superficial bladder cancer with transurethral bladder tumor resection were divided into observation group and control group,control group given HCPT bladder perfusion chemotherapy,observation group given HCPT bladder perfusion combined hyperthermia.Relapse and long-term survival rate were compared.ResultsRecurrence rates of observation group 6 months,1 year,1.5 year,2 years were significantly lower than that control group (3.51% vs 19.30%,10.53% vs 24.56%,14.04% vs 29.82%,14.04% vs 35.09%);2 year survival rate were significantly higher than that control group (87.72% vs 73.68%).ConclusionHCPT bladder perfusion combined hyperthermia therapy can reduce superficial bladder cancer postoperative recurrence rate,improve long-term survival rate.

Key words:Superficial bladder cancer;Hydroxycamptothecin(HCPT);Hyperthermia;Recurrence

膀胱癌是临床发病率较高的恶性肿瘤，其中非肌层浸润性膀胱癌(NMIBC)占发病率的75%。临床多采用经尿道膀胱肿瘤电切术(TURBT)治疗NMIBC患者，但有研究显示，TURBT术后复发率高达50%以上[1]。羟基喜树碱(HCPT)是一种抗肿瘤药物，通过膀胱灌注羟基喜树碱化疗，配合高温加热可有效降低膀胱癌电术后复发率[2]。本院采用羟基喜树碱膀胱灌注联合体外热电场热疗治疗浅表性膀胱癌术后患者，取得了满意的效果。现将研究结果报告如下。

1资料与方法

1.1一般资料研究对象为2010年3月至2013年2月，在本院接受TURBT术的浅表性膀胱癌患者114例，均符合浅表性膀胱癌诊断标准，本次实验报请医院伦理委员会批准，且所有患者均签署知情同意书。……